Allogene Therapeutics (ALLO)

[jondoeuk]

From the recent call, ALLO have disclosed they are already designing next-gen TurboCARs to overcome immunosuppressive TMEs, particularly in solid tumours by engineering T-cell stimulatory domains that are activated by certain factors, such as PD-L1 and TGFb. Also, in concert with Baylor College of Medicine, are exploring the use of alloimmune defense receptors (to overcome rejection) [1].

Other planned improvements include manufacturing and CAR engineering. On top of this, there are twelve solid tumour targets, with two (CD70 [2,3] and DLL3 [4,5]) disclosed.

Refs:
1 https://www.nature.com/articles/s41587-020-0601-5
2 https://www.allogene.com/resources/download/AlloCAR-T-Targeting-CD70-For-RCC.pdf
3 https://www.mdpi.com/2072-6694/11/10/1611/htm
4 https://www.allogene.com/resources/download/Screening-and-Characterization-of-AlloCAR-T.pdf
5 https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS2597